A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Crossref DOI link: https://doi.org/10.1007/s11523-017-0502-9
Published Online: 2017-06-06
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Michael, Michael
Bang, Yung-Jue
Park, Young Suk
Kang, Yoon-Koo
Kim, Tae Min
Hamid, Oday
Thornton, Donald
Tate, Sonya C.
Raddad, Eyas
Tie, Jeanne
Funding for this research was provided by:
Eli Lilly and Company
License valid from 2017-06-06